Correlation of novel ALKATI with ALK immunohistochemistry and clinical outcomes in metastatic melanoma.
Kabeer K ShahJadee L NeffLori A EricksonRory A JacksonSarah M JenkinsAaron S MansfieldJustin C MoserAntoneicka L HarrisJohn A CoplandKevin C HallingThomas J FlottePublished in: Histopathology (2020)
Presence of ALKATI is a good prognostic indicator in MM. ALK IHC and digital molecular analysis can be incorporated into MM evaluation to identify patients with ALKATI for targeted therapy.